Psychedelics in Psychiatry: Early Medical Adoption and Practice-of-Medicine Gray Zones

Psychedelic therapy is increasingly becoming a part of clinical decision making, as evidenced by Compass Pathways’ announcement earlier this year of successful trial results for COMP360 psilocybin for treatment-resistant depression. Kimberly Chew, Senior Counsel, Husch Blackwell LLP, and L. Alison McInnes, MD, MS, Director of Psychedelic Medicine, Mindful Health Solutions, discuss the clinical realities and legal gray zones of psychedelic therapies as they move from controlled trials into real-world practice. They cover recent developments, the gap between clinical trials and clinical practice, Risk Evaluation and Mitigation Strategies, and what good early adoption looks like in the clinical setting. Kimberly and Alison authored a Health Law Weekly article on this topic.

Watch this episode: https://www.youtube.com/watch?v=EE_HTFUWbG8

Read Kimberly and Alison’s Health Law Weekly article: https://www.americanhealthlaw.org/content-library/health-law-weekly/2026/april/10/psychedelics-in-psychiatry-early-medical-adoption

Essential Legal Updates, Now in Audio

AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.

Stay At the Forefront of Health Legal Education

Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.